相关实验视频

Updated: Jul 17, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

使用PD-1过度表达的T细胞膜覆盖的纳米薄膜的cuproptosis-免疫疗法有效地治疗瘤

Tiantian Liu¹, Zehang Zhou², Mengxing Zhang¹

¹Med-X Center for Materials, College of Polymer Science and Engineering, Sichuan University, Chengdu 610065, China.

Journal of controlled release : official journal of the Controlled Release Society

|August 31, 2023

概括

这项研究提出了一种用于向瘤治疗的新型仿生系统 (CuX-P). 在三阴性乳腺癌模型中,CuX-P诱导了cuproptosis,增强了光热疗法,并刺激了抗瘤免疫力.

科学领域:

生物医学工程生物医学工程
癌症治疗癌症治疗
纳米技术纳米技术

背景情况:

质亡是癌症治疗中一个有前途的细胞死亡途径.
有针对性的诱导cuproptosis仍然是一个挑战.
迪苏尔菲拉姆和铜复合物 (DSF/Cu2+) 可以增加PD-L1,阻碍治疗.

研究的目的:

开发一个有针对性的系统,以有效地诱导cuproptosis.
为了克服PD-L1通过DSF/Cu2+的上调调节的挑战.
为三阴性乳腺癌创建多模式治疗系统.

主要方法:

用DSF/Cu2+装载的MXene纳米片被PD-1 T细胞膜 (CuX-P系统) 覆盖.
CuX-P在瘤细胞上准并内化PD-L1.
激光照射与CuX-P治疗相结合.

主要成果:

CuX-P系统有效地准PD-L1,创建一个反循环,以增强内化和cuproptosis诱导.
结合疗法在小鼠模型中显示出显著的抗瘤免疫反应.
成功同时杀死cuproptosis,光热疗法和免疫疗法.

结论:

CuX-P仿生系统为向癌症治疗提供了一种新的策略.
这种方法克服了PD-L1介导的免疫抑制.
该系统显示了通过联合方式治疗三阴性乳腺癌的潜力.

关键词:

生物仿真系统生物仿真系统这种疾病叫做cuproptosis.免疫治疗是一种免疫疗法.纳米薄膜的使用方法

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.